Abkyu

What Abkyu does

Abkyu is a private contract research organization headquartered in Watertown, Massachusetts, that discovers and engineers single-domain antibodies known as VHHs (Variable Heavy chain of Heavy-chain antibodies) on behalf of biotechnology and pharmaceutical partners. The company offers end-to-end VHH discovery services spanning antigen design, camelid immunization, immune repertoire analysis, lead discovery, characterization, and humanization/engineering, and positions itself as a specialist in vivo VHH discovery CRO. Its primary customers are enterprise biotech and pharma companies developing VHH-based therapeutic modalities including bispecifics, multispecifics, cell therapies, antibody-drug conjugates, radiotherapies, and diagnostic imaging agents, with secondary reach into academic research programs.

The technology platform is built around three core pillars: a proprietary DNA immunization system that enables controlled immune priming for difficult and previously intractable targets, next-generation immune repertoire sequencing paired with proprietary bioinformatics pipelines tailored specifically to camelid immune systems, and data-driven hit-prediction workflows that identify VHH leads within 60-90 days. Abkyu deliberately relies on in vivo, non-engineered discovery rather than synthetic or naive in vitro libraries, arguing this captures greater functional diversity, higher-quality affinity maturation, and epitope coverage shaped by biology. Partners retain full ownership of all deliverables, including sequences and cDNA archives, with freedom to advance, publish, or translate discoveries without restriction.

The company generates revenue as a CRO through strategic discovery partnerships, with economic terms that combine upfront payments, development-based milestone payments, and—in some agreements—regulatory/clinical milestones and commercial royalties. Named partners include Jeevan Therapeutics (strategic discovery agreement valued at up to $200 million for colon disease therapeutics), Synap Biotech (neurological recovery therapeutics), Artemia Therapeutics (multi-specific T-cell engagers for autoimmune disease and oncology), and Mosaic Biosciences (preferred partnership). The company markets through direct enterprise outreach, its corporate website, and industry conferences such as the Festival of Biologics. No funding rounds, revenue, or headcount figures are disclosed, and the company appears to operate as a privately held, bootstrapped or selectively funded entity built by founders with decades of VHH discovery experience.

Name

Abkyu

Legal name

Abkyu, Inc.

Website

https://abkyu.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Abkyu is a Watertown, Massachusetts-based contract research organization that discovers and engineers single-domain VHH antibodies for biotech and pharma partners. It offers end-to-end services from antigen design through lead nomination, using proprietary DNA immunization, immune repertoire analysis, and bioinformatics, with revenue from upfront fees, milestones, and royalties.

Ownership category

akta.pro rank

Product category

Contract Research / Antibody Discovery Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• VHH antibody discovery
• Single-domain antibodies
• Contract research services
• Nanobody discovery
• Antibody engineering

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Contract Research Services: Abkyu provides VHH discovery services as a contract research organization, receiving upfront payments and development-based milestone payments. Partners gain access to the company's discovery platform and receive fully owned deliverables. Revenue is generated through project-based fees, upfront payments, and milestone achievements tied to regulatory and clinical progress.
2. Milestone and Royalty Payments: Strategic partnerships include eligibility for regulatory and clinical milestone payments and commercial royalties, providing potential downstream revenue streams based on partner success.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Abkyu is a contract research organization that discovers and engineers single-domain VHH (nanobody) antibodies and provides end-to-end VHH discovery services to biotechnology and pharmaceutical partners. The unified platform covers antigen design and reagent generation, camelid (cell-based, protein, and DNA) immunization, next-generation immune repertoire analysis and lead discovery, biophysical and functional characterization, and sequence/structure-guided humanization and engineering.

Product overview

Abkyu is a VHH (Variable Heavy chain of Heavy-chain antibodies) discovery services company that provides end-to-end single-domain antibody discovery. The company offers a unified platform combining camelid immunization, immune repertoire analysis, VHH discovery, and humanization/engineering services. Key service offerings include Camelid Immunizations (supporting cell-based, protein, and precision DNA immunization approaches), VHH Discovery (combining next-generation sequencing with proprietary bioinformatics), and Humanization and Engineering (sequence- and structure-guided optimization for downstream development). The company operates as a discovery services provider rather than a product-based company, delivering client-owned VHH candidates matched to target product profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• VHH Discovery Services End-to-end contract research service that delivers VHH (single-domain antibody) leads from antigen design through lead nomination for biotech and pharma partners developing VHH-based therapeutics, bispecifics, multispecifics, cell therapies, ADCs, radiotherapies, and diagnostic imaging agents.
• Camelid Immunization Design and Management Design and management of camelid immunization campaigns using cell-based, protein, and proprietary DNA immunization approaches tailored to each target, intended for partners needing controlled immune priming against difficult or intractable antigens.
• Immune Repertoire Analysis and Lead Discovery Next-generation immune repertoire sequencing combined with proprietary camelid-specific bioinformatics and hit-prediction workflows to analyze sequence diversity, clonal expansion, and epitope-associated signatures, enabling identification of candidate VHH leads in 60–90 days.
• Antigen Design and Reagent Generation
• Characterization and Functional Testing Biophysics-, biochemistry-, and cell-based assay services that evaluate affinity, specificity, epitope behavior, and functional activity aligned with each program's mechanism of action to prioritize lead VHH antibodies for downstream development.
• Humanization and Engineering Rational, structure- and sequence-guided humanization and engineering of VHHs using framework selection, targeted mutations, and developability-focused design to optimize stability, manufacturability, and pharmacokinetics while preserving affinity, specificity, and function.

Quantifiable outcome

• Fast VHH identification in 60-90 days
• +2 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and preferred.

• Synap BiotechcoreStrategic or Co-development Partner · 23 June 2026Abkyu entered a strategic discovery agreement with Synap Biotech under which Synap nominates therapeutic targets and Abkyu applies its proprietary VHH discovery platform to identify, engineer, and develop clinical assets. The collaboration focuses on neurological recovery therapeutics targeting stroke, traumatic brain injury, and other neurological disorders. Abkyu receives upfront payments and may be eligible for future development-based milestone payments.
• Artemia TherapeuticscoreStrategic or Co-development Partner · 21 May 2026Abkyu and Artemia Therapeutics formed a strategic partnership to discover and develop novel VHH candidates for Artemia's multi-specific T-cell engager programs targeting autoimmune diseases and oncology. Artemia gains preferred access to Abkyu's integrated VHH discovery and engineering platform while Abkyu receives upfront payment plus development milestones.
• Mosaic BiosciencespreferredStrategic or Co-development Partner · 12 May 2026Abkyu announced a preferred partnership with Mosaic Biosciences to expand VHH discovery capabilities. The partnership provides Mosaic with prioritized access to Abkyu's discovery platform and expertise.
• Jeevan TherapeuticscoreStrategic or Co-development Partner · 2 September 2025Abkyu entered a strategic discovery agreement with Jeevan Therapeutics valued at up to $200 million. The collaboration leverages Abkyu's proprietary VHH discovery platform to develop next-generation therapeutics for colon disease, including autoimmune conditions and colorectal cancer. Jeevan gains dedicated access to Abkyu's discovery platform and downstream engineering expertise. Abkyu receives upfront payment and is eligible for regulatory and clinical milestone payments and commercial royalties.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• GenScript: Global biotech CRO and CDMO offering antibody discovery, synthesis, and engineering services. Provides a broad menu including single-domain antibody work at competitive price points, putting pricing pressure on specialist CROs like Abkyu.
• Lonza: Global CDMO and biologics services provider with antibody discovery and expression capabilities. Competes indirectly via partner networks and offers downstream manufacturing scale that pure-play discovery CROs lack.
• WuXi Biologics: Global biologics CRO/CDMO offering antibody discovery, development, and manufacturing. Provides an integrated alternative for biotechs that prefer to outsource VHH discovery through a single mega-vendor rather than a specialized CRO.
• Charles River Laboratories: Large publicly-traded CRO offering comprehensive antibody discovery and engineering services, including VHH and alternative scaffold capabilities. Competes for biotech discovery outsourcing budgets and brings substantially greater scale and capital.

Direct peers

• Ablynx (Sanofi): Original pioneer of VHH/nanobody therapeutics (acquired by Sanofi in 2018 for ~$4.8B). Source of the foundational IP and platform that defines the VHH category Abkyu operates in; now part of Sanofi's Nanobody® platform and a potential partner or competitor for VHH discovery work.
• Argenx: Commercial-stage VHH therapeutics leader (efgartigimod/VYVGART). Operates the same single-domain antibody modality Abkyu serves as a CRO, and represents both the proof-point for VHH modality demand and a competitor for high-end biotech discovery talent and client mindshare.
• Crescendo Biologics: Clinical-stage VHH-focused biotechnology company with its own T-cell engager (Humabody®) platform. Competes directly for VHH discovery clients and talent, and serves as a benchmark for what a successful VHH platform can become.
• Ossianix: VHH-focused discovery and engineering company developing single-domain antibody therapeutics in CNS and other indications. Closest comparable in scale and stage to Abkyu, with overlapping therapeutic area focus.

Emerging players

• Isogenica: Specialized biotech focused on single-domain antibody (VHH and alternative scaffold) discovery and engineering using proprietary in vitro display technologies. Direct niche competitor in the single-domain antibody CRO space.
• Ablexis (now part of Eli Lilly): Antibody discovery platform company (AlivaMab Human Antibody Discovery) that develops transgenic animal and phage display platforms for human antibody generation. Comparable as a specialized antibody discovery platform, though focused on conventional mAbs rather than VHHs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abkyu